OSAKA, Japan — (BUSINESS WIRE) — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (「Takeda」) today announced that the U.S. Food & Drug Administration (FDA) has accepted for revi…
U.S. Food & Drug Administration Accepts Takeda』s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
OSAKA, Japan — (BUSINESS WIRE) — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (「Takeda」) today announced that the U.S. Food & Drug Administration (FDA) has accepted for revi…